evotec ag second quarter report 2006 dear shareholders during q2 we made significant progress on our central nervous systems cns product pipeline successfully completed the proof of principle study with insomnia drug evt 201 reconfirmed positive findings first same 2 5 mg dose as in previous and determined a more detailed response relationship have filed ind for intend to start phase ii patient us september i alzheimer s disease or neuropathic pain therapeutic 101 after period end realise adequate financial flexibility development expansion secured eur 18 million additional funds through capital increase april collaborative research part services pharmaceuticals businesses it is strategy focus results based projects which customers share success milestone payments royalties thus providing longer term benefits build such partnerships essential that provide access selected promising proprietary discovery know how assets discovered using state
